Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 68: 30-38, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30599445

ABSTRACT

Diabetic patients are at an increased risk of developing severe and progressive periodontitis. Periodontal disease also increases the severity of diabetes by enhancing insulin resistance. Therefore, the regulation of periodontal inflammation in diabetic patients may contribute to the control of both diseases. Glycyrrhizic acid exerts anti-inflammatory effects by inhibiting high mobility group box 1 (HMGB1). HMGB1, one of the ligands of the receptor for advanced glycation end products (RAGE), is a damage-associated molecular pattern and induces inflammatory cytokine production. In the present study, we examined the effects of glycyrrhizic acid on ligature- and Porphyromonas gulae infection-induced periodontitis as well as the involvement of the HMGB1-RAGE axis in diabetic model mice. The molars of diabetic model mice, established by feeding HFD32 to KK/TaJcl mice, were subjected to silk thread ligation and P. gulae was then intraorally applied in the presence or absence of glycyrrhizic acid given topically. The topical application of glycyrrhizic acid suppressed ligature/P. gulae-induced increases in interleukin (IL)-6 and tumor necrosis factor (TNF)-α at the mRNA level in the gingiva and at the protein level in serum. Furthermore, glycyrrhizic acid suppressed ligature/P. gulae-induced increases in serum amyloid A (SAA) in serum and fasting blood glucose levels. It also suppressed ligature/P. gulae-induced increases of HMGB1 and RAGE at the mRNA level in the gingiva and at the protein level in serum. A mouse anti-HMGB1-neutralizing antibody inhibited increases in serum glucose levels. In conclusion, topical treatments with glycyrrhizic acid may suppress periodontal and systemic inflammation and reduce blood glucose levels through the HMGB1-RAGE axis in diabetic mice.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Bacteroidaceae Infections/drug therapy , Diabetes Mellitus, Experimental/drug therapy , Glycyrrhizic Acid/therapeutic use , Hypoglycemic Agents/therapeutic use , Periodontitis/drug therapy , Porphyromonas , Animals , Anti-Inflammatory Agents/pharmacology , Bacteroidaceae Infections/immunology , Bacteroidaceae Infections/pathology , Blood Glucose/drug effects , Cells, Cultured , Cytokines/genetics , Cytokines/immunology , Diabetes Mellitus, Experimental/immunology , Diabetes Mellitus, Experimental/pathology , Fibroblasts/drug effects , Fibroblasts/immunology , Gingiva/immunology , Gingiva/pathology , Glycyrrhizic Acid/pharmacology , HMGB1 Protein/genetics , Hypoglycemic Agents/pharmacology , Male , Mice , Periodontitis/immunology , Periodontitis/pathology
2.
Nucleic Acids Symp Ser (Oxf) ; (49): 349-50, 2005.
Article in English | MEDLINE | ID: mdl-17150777

ABSTRACT

We designed and constructed an allosterically controllable ribozyme with rational molecular design. An allosteric modular unit that is under the control of an organic molecule was installed to an artificially designed ribozyme on the basis of the fact that the RNA is an assemblage of functional modular units. The ribozyme was successfully converted to allosterically controllable form.


Subject(s)
RNA, Catalytic/chemistry , Allosteric Regulation , Base Sequence , Genetic Engineering , Molecular Sequence Data , RNA, Catalytic/drug effects , Theophylline/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...